Objective The aim of this study was to evaluate the pharmacodynamics and safety of
midazolam after intravenous infusion or oral administration in preterm infants. Methods] …

Although midazolam is a frequently used sedative in neonatal intensive care units, its use in
preterm neonates has been off‐label. Recently, a new dosing advice for midazolam for …

Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

Objective: To evaluate the effects of intravenous midazolam on haemodynamic variables
and cerebral blood flow velocity (CBFV) and to determine the pharmacokinetics using a …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

Background Midazolam is used widely as a sedative to facilitate mechanical ventilation. This
prospective study investigated the population pharmacokinetics of midazolam in very …

Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half-life (t 1/2) and the clearance (Cl) are 3.3-fold longer and 3.7-fold …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus (0.2 mg· kg− 1) immediately followed by continuous infusion of 0.06 …

A variety of developmental changes is of influence on the pharmacokinetics and
pharmacodynamics of midazolam in neonatal and pediatric intensive care patients …